Clinical Trials Logo
  1. Home
  2. Anticoagulation
  3. NCT06209892

Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis

Anticoagulation Clinical Trial

Official title:
Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular

Clinical Trial Summary

A single-center, open-label, exploratory randomized controlled study is proposed with the following objectives: whether prolonging the duration of anticoagulation to 12 months, compared with 6 months of routine anticoagulation, helps to reduce major adverse cardiovascular and cerebrovascular events in patients with left ventricular thrombosis and to reduce recurrence of thrombosis, as well as to assess their bleeding risk. Patients with a definite diagnosis of left ventricular thrombus and age ≥18 years were included in cardiac ultrasound (including general ultrasound and sonography) and other examinations during hospitalization and outpatient visits. Exclusion criteria were detailed in the study protocol. GROUPING: According to the duration of anticoagulation, they were divided into extended anticoagulation group (12 months) and conventional anticoagulation group (6 months). INTERVENTION: This study is planned to extend the administration of rivaroxaban (Pulsatilla) 20 mg to 12 months in the experimental group. The conventional anticoagulation group will take the drug for 6 months Study Endpoints: The primary efficacy endpoint is a major cardiovascular-vascular adverse event at 1 year; the primary safety endpoint is bleeding of grade 3 or higher as defined by the BARC classification at 1 year. Patient Follow-up Program: Subjects will require a total of 12 on-site follow-up visits (one per month) for safety evaluation, efficacy evaluation, medication adherence evaluation, and imaging follow-up at months 3, 6, and 12.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06209892
Study type Interventional
Source Chinese Academy of Medical Sciences, Fuwai Hospital
Contact
Status Not yet recruiting
Phase N/A
Start date January 2024
Completion date December 2027
View Details
See also
  Status Clinical Trial Phase
Completed NCT02705976 - Prospective Trial of a Validated Algorithm for Warfarin Dosing N/A
Active, not recruiting NCT04139525 - Comparison of Citrate and Heparin Anticoagulation During Hemodialysis With MCO PES-PVP (Theranova) Membrane N/A
Completed NCT01907048 - Patient and Physician Knowledge of Key Safety Messages
Recruiting NCT03419923 - Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage N/A
Completed NCT03575936 - Enhanced Pharmacist-Managed Anticoagulation Service in a University-based Family Medicine Clinic N/A
Completed NCT02714855 - Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France N/A
Recruiting NCT01314235 - Influence of Clonidine on Thrombozytes of Blood of Patients Under Anticoagulation Therapy With ASS and Clopidogrel N/A
Withdrawn NCT04059965 - AntiCoagulation Tracking InterVention and Evaluation N/A
Recruiting NCT02987192 - Minimally Invasive Lumbar Aneasthesia Used for Cesarean Section N/A
Completed NCT01477528 - Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)
Recruiting NCT04405232 - Coagulopathy in COVID19 - A Multi-Centre Observational Study in UK
Recruiting NCT02761941 - Excessive Warfarin Anticoagulation - Causes and Consequences N/A
Completed NCT02392104 - Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service N/A
Completed NCT01884337 - Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery Phase 4
Recruiting NCT03473132 - Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC) Phase 4
Enrolling by invitation NCT05305612 - Optimal PeriproCeduraL AnticOagulation in Structural Transseptal Interventions Phase 4
Completed NCT03662594 - Growth of High-Quality Oxides on The Inner Surface of ECMO Circuit by ALD to Reduce Thrombus Formation N/A
Active, not recruiting NCT03910933 - Electronic KIDCLOT Interactive Thrombosis/Thrombophilia Education; A Quality Assurance Initiative
Completed NCT02492828 - Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden N/A
Completed NCT03684395 - Accessibility to New Drugs Versus SOC in Sweden